These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 9688305)

  • 1. Effective chemo-immunotherapy of L1210 leukemia in vivo using interleukin-12 combined with doxorubicin but not with cyclophosphamide, paclitaxel or cisplatin.
    Zagozdzon R; Gołab J; Stokłosa T; Giermasz A; Nowicka D; Feleszko W; Lasek W; Jakóbisiak M
    Int J Cancer; 1998 Aug; 77(5):720-7. PubMed ID: 9688305
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potentiatied antitumor effectiveness of combined chemo-immunotherapy with interleukin-12 and 5-fluorouracil of L1210 leukemia in vivo.
    Goł b J; Zagozdzon R; Kamiński R; Kozar K; Gryska K; Izycki D; Mackiewicz A; Stokłosa T; Giermasz A; Lasek W; Jakóbisiak M
    Leukemia; 2001 Apr; 15(4):613-20. PubMed ID: 11368364
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potentiatied anti-tumor effectiveness of combined therapy with interleukin-12 and mitoxantrone of L1210 leukemia in vivo.
    Golab J; Zagozdzon R; Kozar K; Kaminski R; Giermasz A; Stoklosa T; Lasek W; Jakobisiak M
    Oncol Rep; 2000; 7(1):177-81. PubMed ID: 10601614
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interleukin 12-based immunotherapy improves the antitumor effectiveness of a low-dose 5-Aza-2'-deoxycitidine treatment in L1210 leukemia and B16F10 melanoma models in mice.
    Kozar K; Kamiński R; Switaj T; Ołdak T; Machaj E; Wysocki PJ; Mackiewicz A; Lasek W; Jakóbisiak M; Gołab J
    Clin Cancer Res; 2003 Aug; 9(8):3124-33. PubMed ID: 12912964
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination of immunotherapy with cyclophosphamide/actinomycin D chemotherapy potentiates antileukemic effect and reduces toxicity in a L1210 leukemia model in mice.
    Lasek W; Sora M; Wańkowicz A; Jakóbisiak M
    Cancer Lett; 1995 Feb; 89(1):137-43. PubMed ID: 7882296
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The potentiated antileukemic effects of doxorubicin and interleukin-12 combination are not dependent on nitric oxide production.
    Zagozdzon R; Giermasz A; Gołab J; Stokłosa T; Jalili A; Jakóbisiak M
    Cancer Lett; 1999 Dec; 147(1-2):67-75. PubMed ID: 10660091
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potentiation of antitumor effects of IL-12 in combination with paclitaxel in murine melanoma model in vivo.
    Zagozdzon R; Golab J; Mucha K; Foroncewicz B; Jakobisiak M
    Int J Mol Med; 1999 Dec; 4(6):645-8. PubMed ID: 10567677
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Successful chemoimmunotherapy of murine L1210 lymphatic leukemia with cyclophosphamide and mafosfamide-treated leukemia cells.
    Kawalec M; Skórski T; Kawiak J
    Invest New Drugs; 1988 Sep; 6(3):169-72. PubMed ID: 3192382
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adriamycin and cyclophosphamide in combination chemotherapy of L1210 leukemia.
    Avery TL; Roberts D
    Cancer Res; 1977 Mar; 37(3):678-83. PubMed ID: 837368
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined effects of immunity and antitumor drugs against cancer. I. In vivo studies with cis-diamminedichloroplatinum and cyclophosphamide in mouse models.
    Ricci F; De Filippi R; Riccardi C; Romani L; Giuliani A
    Chemioterapia; 1987 Dec; 6(6):403-9. PubMed ID: 3435922
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemotherapy-increased antineoplastic effects of antibody-toxin conjugates.
    Sironi M; Canegrati MA; Romano M; Vecchi A; Spreafico F
    Cancer Treat Rep; 1984 Apr; 68(4):643-5. PubMed ID: 6713420
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chemoimmunotherapy of L1210 leukemia with adriamycin, cyclophosphamide, and OK-432, and their effects on the generation of antitumor immunity.
    Ujiie T
    Jpn J Cancer Res; 1987 Jul; 78(7):737-47. PubMed ID: 3114200
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antileukemic effects of recombinant human tumor necrosis factor alpha (rh-TNF alpha) with cyclophosphamide or methotrexate on leukemia L1210 and leukemia P388 in mice.
    Warzocha K; Robak T
    Acta Haematol Pol; 1992; 23(1):55-62. PubMed ID: 1615753
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination chemotherapy of L1210 leukemia with platinum compounds and cyclophosphamide plus other selected antineoplastic agents.
    Glae GR; Atkins LM; Meischen SJ; Smith AB; Walker EM
    J Natl Cancer Inst; 1976 Dec; 57(6):1363-6. PubMed ID: 187805
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined interferon--antimetabolite therapy of murine L1210 leukemia.
    Slater LM; Wetzel MW; Cesario T
    Cancer; 1981 Jul; 48(1):5-9. PubMed ID: 6165457
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Augmented antitumor effects of combination therapy with interleukin-12, cisplatin, and tumor necrosis factor-alpha in a murine melanoma model.
    Zagozdzon R; Stokłosa T; Gołab J; Giermasz A; Dabrowska A; Lasek W; Jakóbisiak M
    Anticancer Res; 1997; 17(6D):4493-8. PubMed ID: 9494557
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined therapy of mice bearing L1210 leukemia with adriamycin and mycobacteria.
    Fiszer L; Mordarski M
    Arch Immunol Ther Exp (Warsz); 1978; 26(1-6):873-9. PubMed ID: 749836
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemotherapy and immunotherapy of L1210 leukemic mice with antigenic tumor sublines.
    Nicolin A; Canti G; Marelli O; Veronese F; Goldin A
    Cancer Res; 1981 Apr; 41(4):1358-62. PubMed ID: 7011535
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers.
    Pegram M; Hsu S; Lewis G; Pietras R; Beryt M; Sliwkowski M; Coombs D; Baly D; Kabbinavar F; Slamon D
    Oncogene; 1999 Apr; 18(13):2241-51. PubMed ID: 10327070
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemotherapy of advanced L1210 leukemia with platinum compounds in combination with other antitumor agents.
    Gale GR; Atkins LM; Meischen SJ; Smith AB; Walker EM
    Cancer Treat Rep; 1977; 61(3):445-50. PubMed ID: 872142
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.